Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.66 |
| ▸ | MTOR | P42345 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.57 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.55 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | STK16 | O75716 | 1/20 | 0.55 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396499 | 0.95 | PIK3CA (0.64) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL12264531 | 0.92 | PIK3CA (0.70) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1497485 | 0.87 | PIK3CA (0.65) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1497626 | 0.86 | PIK3CA (0.63) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1497624 | 0.86 | PIK3CA (0.63) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1865477 | 0.86 | PIK3CA (0.78) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL2395995 | 0.85 | PIK3CA (0.64) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1497490 | 0.85 | PIK3CA (0.63) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL1497549 | 0.84 | PIK3CA (0.62) | PIK3CAMTORABCC4ABCB11PIK3CD | |
| SCHEMBL2399959 | 0.83 | PIK3CA (0.58) | PIK3CAMTORABCC4ABCB11PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885MTOR 37/4885ABCC4 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.